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Introduction
Systemic lupus erythematosus (SLE) is one of the most-
investigated autoimmune disorders, characterized by a 
systemic inflammatory reaction. It affects nearly all vital 
organs and tissues and is characterized by a wide spec-
trum of clinical signs and symptoms.
The diagnosis of SLE is based on thorough clinical 
assessment of the patient. The disease course is fluctuat-
ing, characterized by acute and often severe exacerba-
tions. Several scoring systems have been validated to 
measure disease activity (Griffiths et al. 2005); however, 
no objective laboratory marker has been identified that 
can reliably be used for the detection of ongoing inflam-
mation in correlation with clinical symptoms in SLE.
Nowadays C reactive protein (CRP) is regarded as the 
gold-standard for the assessment of systemic inflamma-
tion. It is used not only in infections, but also in several 
immune-mediated conditions, such as rheumatoid 
arthritis (RA). However, in SLE, CRP levels are often not 
elevated. Previous studies demonstrated a failure of the 
acute phase CRP response during active lupus despite 
evident tissue inflammation (Russell et al. 2004). In 
clinical practice, a significantly elevated erythrocyte 
sedimentation rate (ESR) with a normal CRP is a strong 
indicator of SLE. ESR is, however, a rather unspecific 
marker of inflammation.
It is not completely clear why – in contrast with other 
rheumatic diseases – SLE is characterized by a low 
CRP response, in spite of a significant degree of tissue 
inflammation. Induction of CRP synthesis in hepatocytes 
is regulated by pro-inflammatory cytokines, most 
importantly by IL-6, IL-1b and TNF-a. Liou demonstrated 
that serum levels of these cytokines in patients with 
untreated lupus were higher than in controls, but still 
lower compared to RA. Furthermore, cytokine and CRP 
levels were not proportionally correlated, indicating 
that these cytokines might insufficiently induce CRP 
synthesis in SLE (Liou 2001).
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Objective: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker of systemic inflammation. We 
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Over the recent years, soluble urokinase plasmino-
gen activator receptor (suPAR) has been described as a 
valuable indicator of the activation state of the immune 
system. Urokinase-type plasminogen activator recep-
tor (uPAR) is expressed on various cell types, including 
immune, smooth muscle and endothelial cells (Danø 
et al. 1994; Behrendt & Stephens 1998). This membrane 
protein may be cleaved from the cell surface, thus form-
ing a free soluble receptor, suPAR (Stephens et al. 1997). 
suPAR is detectable in low, but practically constant 
concentrations in plasma of healthy individuals (Rønne 
et al. 1995; Stephens et al. 1997). However, an inflamma-
tory response leads to elevated plasma suPAR levels, as 
reported in conditions such as infectious (Ostergaard 
et al. 2004; Ostrowski et al. 2005), autoimmune (Balabanov 
et al. 2001), neoplastic (Sier et al. 1998) and pregnancy-
related (Toldi et al. 2011) diseases. Importantly, higher 
levels of suPAR were proportional to a worse prognosis 
in the above conditions (Sier et al. 1998; Ostergaard et al. 
2004; Ostrowski et al. 2005).
suPAR’s high stability in plasma samples makes it an 
ideal candidate as a potential clinical marker. In con-
trast to CRP, suPAR levels are stable throughout the day 
in healthy individuals, independently of whether the 
subject is fasting or not (Sier et al. 1999). Even repeated 
freeze-thaw procedures of plasma samples did not affect 
suPAR concentrations (Riisbro et al. 2001).
In this study, we aimed to determine plasma suPAR 
levels in SLE patients compared to healthy individuals 
in order to reveal if suPAR could serve as an activity bio-
marker in this disease, and differentiate between clinical 
SLE subgroups.
Methods
Study participants
Eighty-nine SLE patients with various stages of disease 
duration and activity and 29 healthy individuals were 
enrolled in this study. SLE patients were diagnosed and 
classified according to the updated American College 
of Rheumatology (ACR97) criteria (Hochberg 1997). 
Clinical parameters of study participants are summarized 
in Table 1. All SLE patients were diagnosed at least two 
years before sampling. The median of SLE duration was 8 
years, and the median of Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) score was 2, correspond-
ing to moderate disease activity (Griffiths et al. 2005). 
SLEDAI scores were calculated at the time of sampling. 
Patients were treated with the following medications: 
methylprednisolone (73%), chloroquine (45%), aza-
thioprine (21%), cyclophosphamide (11%), methotrex-
ate (11%), cyclosporin (4%), and mycophenolate mofetil 
(2%). Healthy controls were volunteer blood donors and 
had a negative history of rheumatic symptoms and nega-
tive status upon detailed physical and routine laboratory 
examination. Written informed consent was obtained 
from all subjects, and our study was reviewed and 
approved by an independent ethical committee of the 
institution. Laboratory studies and interpretations were 
performed on coded samples lacking personal and diag-
nostic identifiers. The study was adhered to the tenets of 
the most recent revision of the Declaration of Helsinki.
Laboratory procedures
Plasma was isolated from EDTA anticoagulated fast-
ing blood samples and stored at −80°C until measure-
ment. Plasma suPAR concentrations were measured 
with the suPARnostic Flex ELISA assay (ViroGates A/S, 
Birkerød, Denmark). hs-CRP levels were measured using 
a Roche Hitachi 912 instrument with Roche Tina-quant 
CRP immuno-turbidimetric assay (Roche Diagnostics 
GmbH, Mannheim, Germany). For the determination 
of erythrocyte sedimentation rate (ESR), the Westergren 
method was performed according to ICSH specifica-
tions (International Council for Standardization in 
Haematology 1993) on undiluted EDTA anticoagulated 
blood samples using glass pipettes (Greiner Bio-One, 
Kremsmuenster, Austria). During sedimentation, the 
pipettes were mounted vertically on appropriate sup-
porting racks and kept at room temperature, which never 
exceeded 25°C.
Statistics
Data are expressed as median [interquartile range]. 
CRP values below the level of detection (1 mg/L) were 
regarded as 1 mg/L. Comparisons between healthy 
individuals and SLE patients were made with Mann-
Whitney tests. In case of comparisons between healthy 
controls and SLE patient subgroups, the Kruskal–Wallis 
test was performed. To study the independent effect of 
the investigated variables, multiple regression analysis 
was used. AUC values of receiver operating charac-
teristics (ROC) curves were calculated using standard 
methods and data are presented as AUC ROC (95% CI). 
Table 1. Clinical characteristics of healthy individuals and 
systemic lupus erythematosus (SLE) patients.
Characteristics
Healthy 
individuals 
(n = 29)
SLE patients 
(n = 89) p value
Age (years) 55 [46–69] 44 [34–59] 0.25
Gender (male/female) 10/18 10/79 –
SLE duration (years) – 8 [3–13] –
SLEDAI – 2 [0–5] –
Anti-DNA (IU/mL) – 26 [12–67] –
C3 (mg/dL) – 107 [76–130] –
C4 (mg/dL) – 17 [12–23] –
suPAR (ng/mL) 2.80 [2.06–3.42] 4.58a [3.72–6.30] 0.0001
CRP (mg/L) 2.70 [BLD-4.15] 3.90 [BLD-9.55] 0.14
ESR (mm/h) 10 [7–14] 28a [17–50] 0.0001
Data are expressed as median [interquartile range].
ap < 0.01 vs. healthy individuals.
BLD, below the level of detection, CRP, C reactive protein, 
ESR, erythrocyte sedimentation rate, SLE, systemic lupus 
erythematosus, SLEDAI, systemic lupus erythematosus disease 
activity index, suPAR, soluble urokinase plasminogen activator 
receptor.
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p values < 0.05 were considered significant. Statistics 
were calculated using the SPSS software (version 20.0, 
SPSS, Inc. Chicago, IL, USA).
Results
suPAR and ESR values were higher in SLE patients than 
in controls, while CRP levels were comparable (Table 1, 
Figure 1).
We performed further analyses of suPAR levels based 
on several subgroups of SLE patients. We investigated 
patients with or without the following factors occurring 
in their history: arthritis (89%), photosensitivity (67%), 
butterfly rash (20%), other skin lesion (42%), serosi-
tis (37%), pericarditis (30%), pleuritis (38%), nephri-
tis (46%), Raynaud’s phenomenon (56%), vasculitis 
(28%), thromboembolism (20%), adenomegaly (36%), 
splenomegaly (11%), secondary Sjögren’s syndrome 
(20%), hemolytic anemia (hematocrit < 0.35, 13%), non-
hemolytic anemia (hematocrit < 0.35, 65%), leukopenia 
(leukocyte count < 4000/mm3, 62%), lymphopenia (lym-
phocyte count < 1500/mm3, 61%), thrombocytopenia 
(thrombocyte count < 100000/mm3, 19%), anti-DNA 
antibody positivity (81%), anti-SSA antibody positiv-
ity (52%), anti-SSB antibody positivity (35%), anti-Sm 
antibody positivity (26%), anti-RNP antibody positivity 
(22%), anti-CL antibody positivity (42%), anti-beta2GPI 
antibody positivity (29%), lupus anticoagulant positivity 
(activated partial thromboplastin time > 40 s, 30%), low 
C3 complement level (78%), low C4 complement level 
(57%) and Coombs positivity (17%).
suPAR levels of patients with vasculitis in their history 
(28%) was higher than that of patients with no vasculitis 
(5.84 [4.12–7.01] vs. 4.21 [3.57–5.47] ng/mL, p = 0.04). 
In cases of all other comparisons, no differences were 
detected between lupus patient subgroups in suPAR 
levels.
When SLE patients were divided into subgroups 
based on CRP (≤5 mg/L and >5 mg/L) and ESR values 
(≤20 mm/h and >20 mm/h), no difference was detected 
in suPAR levels between the subgroups (Table 2).
suPAR, CRP and ESR values were also analyzed in 
SLE patient subgroups based on SLEDAI scores (Table 3, 
Figure 2). Patients with a SLEDAI score of 0 were consid-
ered to be in remission, a SLEDAI score between 1 and 8 
was regarded as moderate disease activity, and a SLEDAI 
score above 8 was regarded as high disease activity. In 
case of CRP and ESR values, no difference was detected 
between SLE patients grouped according to SLEDAI 
scores. However, interestingly, suPAR levels in patients 
with high disease activity were higher than in patients 
with moderate disease activity or patients in remission.
ROC analysis of suPAR values in healthy individu-
als and SLE patients yielded an AUC of 0.85 (95% CI: 
0.77–0.93, p = 0.0001, Figure 3). The cut-off value of 
suPAR to discriminate between healthy individuals and 
SLE patients was 3.54 ng/mL (sensitivity% (95% CI): 
82.02 (72.45–89.63), specificity% (95% CI): 79.31 (60.28–
92.01)). ROC analysis of CRP levels in healthy individuals 
and SLE patients did not present a statistically significant 
AUC value. ROC analysis of ESR values in healthy indi-
viduals and SLE patients provided an AUC of 0.87 (95% 
CI: 0.80–0.94, p = 0.0001).
ROC analysis of suPAR values in SLE patients accord-
ing to SLEDAI scores yielded an AUC of 0.68 (95% CI: 
0.50–0.86, p = 0.04, Figure 3). The cut-off value of suPAR 
to discriminate between patients with high disease activ-
ity (SLEDAI > 8) and those with moderate disease activity 
or in remission (SLEDAI ≤ 8) was 5.70 ng/mL (sensitiv-
ity% (95% CI): 61.54 (31.58–86.14), specificity% (95% CI): 
78.72 (64.34–89.30)). ROC analysis of CRP and ESR val-
ues in SLE patients according to SLEDAI scores did not 
present a statistically significant AUC value.
Discussion
We have demonstrated that plasma levels of suPAR, a 
novel marker of systemic inflammation are elevated in 
lupus patients compared to healthy individuals (cut-off 
value: 3.54 ng/mL). ESR values were also higher in the 
SLE group, while CRP levels were comparable in the 
healthy and diseased groups. Of note, the SLE group had 
a higher female to male ratio compared to the control 
group, in line with unequal gender prevalence of the 
disease. The effect of gender on our results cannot be 
excluded, since according to earlier data, slightly higher 
Figure 1. Comparison of soluble urokinase plasminogen activator receptor (suPAR) plasma levels, C reactive protein (CRP) plasma levels and 
erythrocyte sedimentation rate (ESR) in healthy individuals and systemic lupus erythematosus (SLE) patients. Horizontal line: median; box: 
interquartile range; whisker: range. ap < 0.05 vs. healthy individuals.
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suPAR concentrations were observed in serum from 
females compared to males (Stephens et al. 1997).
When CRP levels rise above 60 mg/L in febrile SLE 
patients, it is highly sensitive for infection. In contrast, 
in SLE without infection, CRP levels are only moderately 
raised even in patients with very active disease (ter Borg 
et al. 1990). Over the recent years, at least three contributing 
factors have been proposed to understand why CRP levels 
are lower in SLE compared to other inflammatory auto-
immune disorders, such as RA (de Carvalho et al. 2007). 
These include the different responsiveness of monocytes 
producing CRP-inducing cytokines in SLE (Liou 2003), 
and the role of human CRP gene polymorphisms. Two 
of these, CRP 2 and CRP 4, were associated with lower 
CRP levels. Moreover, the CRP 4 allele was also linked 
with the future development of SLE (Russell et al. 2004). 
Third, among several autoimmune disorders, Sjöwall 
et al. (2002) investigated SLE patients for autoantibodies 
to CRP. Serum anti-CRP autoantibodies were found in 
almost half of SLE patients, whereas no anti-CRP antibod-
ies were detected in any of the samples from patients with 
RA, Crohn’s disease or ulcerative colitis. Szyper-Kravitz 
and Shoenfeld (2006) have recently suggested that anti-
CRP autoantibodies, by binding or inactivating CRP, a 
molecule involved in the clearance of apoptotic cells, may 
serve as the promoter of autoimmunity in SLE.
Our results suggest that suPAR levels are higher in SLE 
patients with vasculitis in their history than in patients 
without vasculitis. Experimentally, lower expression of 
uPAR on the endothelial cell surface is associated with 
up to 60% reduced cellular adhesion and extravasation 
of inflammatory cells into the intima of vessel walls (May 
et al. 2000). A study by May et al. (2000) elucidated a novel 
activation pathway of beta(2) integrin-dependent cell-
to-cell adhesion during inflammation that requires uPAR 
as an activation transducer. In their experiments, adhe-
sion was reconstituted when soluble recombinant uPAR 
was allowed to reassociate with the cells. Although we 
did not aim to investigate endothelial uPAR expression 
in our study, one might hypothesize that inflammatory 
cell adhesion to endothelial cells leading to extravasa-
tion into the intima is promoted by higher suPAR levels 
leading to the development of vasculitis in patients with 
elevated plasma suPAR levels. suPAR might promote cell 
adhesion by binding to very late antigen-4 (VLA-4) on 
inflammatory cells as a ligand, promoting their extrava-
sation via the activation of other molecules regulating 
cellular adhesion and migration (Tarui et al. 2001).
Table 2. Soluble urokinase plasminogen activator receptor 
(suPAR) levels in subgroups of systemic lupus erythematosus 
(SLE) patients according to inflammatory parameters.
Study group suPAR (ng/mL)
Healthy individuals 2.80 [2.06–3.42]
SLE patients according to CRP values
 ≤5 mg/L (58.4%) 4.09a [3.46–5.94]
 >5 mg/L (41.6%) 5.00a [4.12–7.19]
SLE patients according to ESR values
 ≤20 mm/h (38.2%) 4.02a [3.01–5.51]
 >20 mm/h (61.8%) 4.83a [3.94–6.92]
Data are expressed as median [interquartile range].
ap < 0.05 vs. healthy individuals.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; 
SLE, systemic lupus erythematosus; suPAR, soluble urokinase 
plasminogen activator receptor.
Table 3. Inflammatory parameters in systemic lupus 
erythematosus (SLE) patients according to Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI).
Study group suPAR (ng/mL) CRP (mg/L) ESR (mm/h)
Healthy 
individuals
2.80 [2.06–3.42] 2.70 [BLD-4.15] 10 [7–14]
SLE patients according to SLEDAI score
 0 (32.6%) 4.09a [3.45–7.53] 4.20 [BLD-8.20] 27a [15–50]
 1–8 (52.8%) 4.58a [3.75–5.41] 2.20 [BLD-10.10] 29a [15–51]
 >8 (14.6%) 6.70a,b,c 
[4.17–8.71]
6.70a 
[3.14–18.60]
36a 
[21–47]
Data are expressed as median [interquartile range].
ap < 0.05 vs. healthy individuals.
bp < 0.05 vs. SLE patients according to SLEDAI score 0.
cp < 0.05 vs. SLE patients according to SLEDAI score 1–8.
BLD, below the level of detection; CRP, C reactive protein; ESR, 
erythrocyte sedimentation rate; SLE, systemic lupus erythematosus; 
SLEDAI, systemic lupus erythematosus disease activity index; 
suPAR, soluble urokinase plasminogen activator receptor.
Figure 2. Comparison of soluble urokinase plasminogen activator receptor (suPAR) plasma levels, C reactive protein (CRP) plasma levels 
and erythrocyte sedimentation rate (ESR) in healthy individuals and systemic lupus erythematosus (SLE) patients grouped according to 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. Patients with a SLEDAI score of 0 were considered to be in remission, 
a SLEDAI score between 1 and 8 was regarded as moderate disease activity, and a SLEDAI score above 8 was regarded as high disease activity. 
Horizontal line: median, box: interquartile range, whisker: range. ap < 0.05 vs. healthy individuals, bp < 0.05 vs. SLE patients with SLEDAI 0, 
cp < 0.05 vs. SLE patients with SLEDAI 1–8.
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Importantly, our results indicate that suPAR, in con-
trast with CRP and ESR, is a marker that may help to 
discriminate between patients with high disease activity 
(SLEDAI > 8) and those with moderate disease activity or 
in remission (SLEDAI ≤ 8). Therefore, with a calculated 
cut-off value of 5.70 ng/mL, suPAR levels may be consid-
ered as an objective marker of highly active SLE. Based 
on our recent findings, suPAR levels are also elevated in 
RA patients, and are is associated with the number of 
swollen joints (Toldi et al. 2012). Therefore, suPAR might 
be regarded as a general marker of disease activity in 
patients with autoimmune disease.
conclusions
Unlike CRP levels, suPAR values are higher in SLE patients 
than in healthy controls. The assessment of inflammation 
is of special importance in the timely detection and treat-
ment of potentially dangerous flares of SLE. So far, ESR 
has been the most widely used parameter to describe the 
inflammatory reaction in SLE. However, suPAR is a more 
stable and reliable parameter for the detection of inflam-
mation than ESR, which might be influenced by several 
other factors (such as anemia). In further contrast with 
ESR, suPAR might be especially suitable for identifying 
patients with active disease, since suPAR values are ele-
vated in patients with high disease activity in comparison 
with moderate disease activity lupus patients and those in 
remission. Hence, suPAR represents an objective clinical 
marker that can reliably be used for the detection of ongo-
ing inflammation with respect to disease severity in SLE.
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